MAURITIUS
CERVICAL CANCER PROFILE

Morbidity and Mortality
Crude cervical cancer incidence per 100,000 women (2020): 19.1
Age-standardized cervical cancer incidence per 100,000 women (2020): 12.6
Cumulative risk of cervical cancer, ages 0-74 (2020): 1.3%
Cervical cancer deaths (2019): 49
Cervical cancer mortality-to-incidence ratio (2020): 0.5
Population-based cancer registry exists (2021): Yes

Primary Prevention
HPV vaccination programme coverage among girls (2020)
Programme coverage*
Coverage by age 15†
0% 20% 40% 60% 80% 100% % of target population
First dose
Final dose
74% 82%
No data

HPV vaccination programme (2020):
HPV included in national vaccination programme: Yes
Scale of vaccination programme: National
Year of introduction: 2016
Primary target cohort: 9 years

Related risk factors:
Tobacco use prevalence, women aged 15+ years (2020)**: 3%
Condom use at last high-risk sex (-): ND
HIV incidence per 1000, women aged 15+ years (2020): 0.56

Secondary Prevention
National screening programme for cervical cancer exists (2021): No
Primary screening test used (2021): -
Target age range of programme (2021): -
Programme/guidelines exist to strengthen early detection of first symptoms at primary health care level (2021): No
Clearly defined referral system exists from primary care to secondary and tertiary care (2021): No

Screening for cervical cancer (2019)
Screened in last 5 years
Ever screened
0% 20% 40% 60% 80% 100% % of women aged 30 - 49 years
23% 42%

Treatment and Supportive Care
National guidelines on cervical cancer management exist (2021): No

Cancer diagnosis and treatment services generally available (2021):
Cancer centre or cancer department at tertiary level: Yes
Pathology services (laboratories): Yes
Cancer surgery: Yes
Chemotherapy: Yes
Radiotherapy: Yes

 Palliative care for patients with NCDs in the public health system generally available (2021):
In primary health care facilities: No
In community or home-based care: No

WHO Cervical Cancer Elimination Strategy Targets for 2030
90% of girls fully vaccinated with the HPV vaccine by the age of 15
70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age
90% of women identified with cervical disease receive treatment

ND = data not available
* Programme coverage: % of national target population (among 9-14-year-old girls)
† Coverage by age 15: % of population turning 15 that have been vaccinated against HPV at any time between ages 9 to 14
** Data refer to tobacco smoking only, in absence of sufficient data on all tobacco use
See Explanatory Notes for indicator descriptions.